Please provide your email address to receive an email when new articles are posted on . The decision is supported by positive visual acuity gains found in the phase 3 QUASAR trial. This is the fourth ...

After unsheathing just a few months ago, Ollin Biosciences’ next-gen bispecific antibody cleared more disease faster than Genentech’s Vabysmo for patients with diabetic macular edema (DME) in an early ...

BGE-102 has the potential for therapeutic retinal exposure with oral delivery, reducing treatment burden in ocular indications currently treated ...

In both studies, Vabysmo was found to be noninferior to aflibercept, with average vision gains being comparable between the treatment groups. The Food and Drug Administration (FDA) has approved ...

The optic cup and macula of a 24-year-old female. Image is released to Wikimedia commons with patient consent. Imaged with a non-mydriatic fundus camera at Pacific University College of Optometry.

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Brolucizumab ...

Patients with retinal diseases who were treated with anti-VEGF therapies through manufacturer patient assistance programs ...

Ollin Biosciences, Inc. (Ollin), a clinical-stage biotech advancing best-in-disease therapies for vision-threatening diseases, today announced positive topline results from its randomized, ...

Vabysmo now covered across all three approved indications in the province, providing patients with a comprehensively funded option for their needs "This expansion in coverage for people with RVO in ...

September 21, 2012 — The US Food and Drug Administration (FDA) has approved aflibercept injection (Eylea, Regeneron Pharmaceuticals) for treating macular edema following central retinal vein occlusion ...